Effects of Risinatide Combined with Benazepril on Blood Glucose and Blood Pressure,Intestinal Microecology and Target Organ Damage in Pa-tients with Metabolic Syndrome
ZHANG Yuhong
SONG Fenglian
CHEN Yong
Abstract:Objective To investigate the effects of Risinatide combined with Benazepril on blood glucose,blood pres-sure,intestinal microecology and target organ damage(TOD)in patients with metabolic syndrome.Methods In total,126 patients with metabolic syndrome from June 2020 to May 2022 were selected and divided into Benazepril group,Risinatide group and combination group according to different treatment methods,and were respectively treated with Benazepril,Risinati-de,and Benazepril combined with Risinatide.Blood glucose,blood pressure,intestinal microecological indexes,TOD and adverse reactions were analyzed before and after treatment in the three groups.Results At 6 months after treatment,fasting blood glucose,2 h postprandial blood glucose,glycated hemoglobin in combination group were the lowest,followed by Lisen-atide group and Benazepril group,and diastolic blood pressure and systolic blood pressure were the lowest in combination group,followed by Benazepril group and Lisenatide group(P<0.05).At 6 months after treatment,Lactobacillus,bifidobac-terium and yeast were higher in combination group than in Risinatide group and Benazepril group,while enterobacter was lower in the combination group than in Risinatide group and Benazepril group(P<0.05).At 6 months after treatment,the total in-cidence of TOD in combination group was lower than that in Risinatide group and Benazepril group(P<0.05).There was no significant difference in intestinal microecological indexes and the total incidence of TOD between Lisinatide group and Benaze-pril group(P>0.05).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion Risinatide combined with Benazepril is safe and reliable for regulating intestinal microecology,lowering blood pressure and blood glucose,and reducing TOD in patients with metabolic syndrome.
Keywords:Metabolic syndromeBenazeprilLisenatideFasting blood glucoseBlood pressureIntestinal micro-ecologyTarget organ damageDrug toxicity
Publication Date:2023-10-22
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:5( 96-100 )
